SomaLogic is joining forces with the US Food and Drug Administration’s Division of Applied Regulatory Science to potentially streamline biosimilar development, using the US-based clinical diagnostic firm’s proprietary protein measurement platform technology to identify circulating pharmacodynamic biomarkers for reference biologics.
The five-year agreement will see data generated on the SomaLogic SomaScan Platform – which makes 5,000 protein measurements simultaneously in...






